Image Source: Pixabay

TM Editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Hypera SA (HYPMY) is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics.

Hypera also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare, and the Non-Retail Market.

The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018.

Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Three key data points gauge Hypera or any dividend-paying firm.

The key three are:

(1) Price

(2) Dividends

(3) Returns

Those three keys also best tell whether any company has made, is making, and will make money.

HYPMY Price

Over the past year, Hypera's share price fell about 31% from $7.67 to $5.30 as of Tuesday’s market close. In the past fourteen years, the company’s share price has never been less than $3.50 nor higher than $18.20.

If Hypera shares trade in the range of $4.50 to $7.00 this next year, the recent $5.30 share price might reach $6.30 in a year. Of course, HYPMY's price could also drop about the same $1.00 estimated amount or more.

My $1.00 upside estimate based on past periodic September to September performance from even to odd numbered years.

HYPMY Dividend

Hypera SA has paid variable annual semi-annual, quarterly and now monthly dividends since May 2016.  The most recent $0.0176 Monthly dividend was declared on July 22nd for shareholders of record on August 1st  and has not been paid. HYPMY has not paid any dividends since January, 2023.  A forward looking $.21 annual dividend would yield 3.98% at Tuesday’s closing price.

HYPMY Returns

Putting it all together, a $1.00 estimated one year gross gain per share shows up when adding Hypera’s $0.00 estimated annual dividend to the estimated price upside of $1.00, making that $1.00 gross gain per share total.

A little over $1000 buys us 189 shares at the $5.30 share price.

A $10 broker fee (if charged), paid half at purchase and half at sale, might take about $0.05 per share out of the $1.00 annual estimated gross-gain to give us a net gain of $0.95 X 189 shares = $179.55 for about a 17.8% estimated net gain for the year.

However, the $0.00 annual dividend income from $1K invested is unacceptable. By these numbers, Hypera may be an ideal dividend dog when its dividend is restored.

Then, you might choose to pounce on Hypera It is a 25 year-old variable dividend-paying Brazil-based  generic pharmaceuticals source with a sporadic record paying dividends.

The exact track of Hypera’s future price and dividend will entirely be determined by market action.

Remember the true value of any stock is best realized through personal ownership of shares.

More By This Author:

Current Report: Getinge
Current Report: Bristol-Meyers Squibb (BMY)
Current Report: Mercedes Benz Group